We've noticed that you're using an ad blocker

Our content is brought to you free of charge because of the support of our advertisers. To continue enjoying our content, please turn off your ad blocker.

It's off now Dismiss How do I disable my ad blocker?
❌

How to disable your ad blocker for our site:

Adblock / Adblock Plus
  • Click on the AdBlock / AdBlock Plus icon on the top right of your browser.
  • Click “Don’t run on pages on this domain.” OR “Enabled on this site.”
  • Close this help box and click "It's off now".
Firefox Tracking Prevention
  • If you are Private Browsing in Firefox, "Tracking Protection" may casue the adblock notice to show. It can be temporarily disabled by clicking the "shield" icon in the address bar.
  • Close this help box and click "It's off now".
Ghostery
  • Click the Ghostery icon on your browser.
  • In Ghostery versions < 6.0 click “Whitelist site.” in version 6.0 click “Trust site.”
  • Close this help box and click "It's off now".
uBlock / uBlock Origin
  • Click the uBlock / uBlock Origin icon on your browser.
  • Click the “power” button in the menu that appears to whitelist the current website
  • Close this help box and click "It's off now".
  • ONCOLOGY
  • News
  • Blogs
  • Topics
  • Hematology
  • Image IQ
  • Podcasts
  • Videos
  • Slideshows
  • Conferences

Modern Medicine Network
  • Login
  • Register
Skip to main content
Modern Medicine Network
  • Login
  • Register
Menu
User
Home
  • ONCOLOGY
  • News
  • Blogs
  • Topics
  • Hematology
  • Image IQ
  • Podcasts
  • Videos
  • Slideshows
  • Conferences

SUBSCRIBE: Print / eNewsletter

Allogeneic Stem Cell Transplants: Supportive Care Is Key

Dec 1, 2000
Volume: 
9
Issue: 
12

HOUSTON—Supportive care for patients undergoing allogeneic
hematopoietic stem cell transplantation presents a series of
challenges, from regimen-related toxicity to chronic
graft-versus-host disease (GVHD), said Daniel Couriel, MD, assistant
professor of blood and marrow transplantation, M.D. Anderson Cancer
Center.

Dr. Couriel discussed current transplant management strategies at
“Medical Oncology: A Comprehensive Review,” an oncology
board review sponsored by M.D. Anderson.

The potential complications associ-ated with stem cell
transplantation can be viewed in terms of regimen-related toxicities,
graft failure, infectious complications, and acute or chronic GVHD,
Dr. Couriel said. These complications occur within a general time
frame that begins at day 0 (the day of the stem cell infusion) and
continues beyond day 100 (the cutoff point used to distinguish acute
vs chronic GVHD).

The earliest problems are directly related to the chemotherapy or
radiotherapy regimen, Dr. Couriel said. Gastrointestinal toxicity,
such as mucositis, is common. Among genitourinary complications,
hemorrhagic cystitis is still a problem, he noted, and is often
related to adenovirus or polyomavirus infections.

Cardiotoxicity—hemorrhagic carditis or myocarditis—is rare
today, he said, as more radiotherapy regimens now rely on
fractionated dosages instead of total body irradiation.

Veno-occlusive disease is another potential regimen-related
complication. The problem typically arises within 30 days of the
transplant, most often between day 7 and day 21. Symptoms include
jaundice, hepatomegaly and right-upper-quadrant pain, and ascites or
weight gain.

Factors that predispose a patient to veno-occlusive disease are high
SGOT, active infection, total body irradiation, and chemotherapy
regimens including oral busulfan (Myleran) (less often, IV busulfan),
carmustine (BCNU), or mitomycin C (Mutamycin).

Anecdotal evidence suggests that prostaglandin E2 along with tissue
plasminogen activator (TPA) may be effective against veno-occlusive
disease, Dr. Couriel said, but the approach is by no means standard
of care.


Idiopathic Interstitial Pneumonia

Idiopathic interstitial pneumonia is a serious complication with a
mortality of approximately 50%. Patients can develop it up to 6
months after transplant, but the problem usually arises between day
30 and day 90. The risk increases with age, prior radiotherapy, and
preexisting lung disease.

“The term ‘idiopathic’ is relative,” Dr. Couriel
said. “A lot of the idiopathic part has to do with the fact that
10 or 15 years ago, we lacked the diagnostic capacity that we have
now. Today, probably only about 5% to 10% of patients with bilateral
pulmonary infiltrates don’t have a diagnosis.”

Because idiopathic interstitial pneumonia is more common among
patients receiving total body irradiation, he added, many of the
early cases probably could have been classified as radiation
pneumonitis.

Diffuse alveolar hemorrhage also is better recognized today—and
may explain another large portion of the “idiopathic”
cases. “At M.D. Anderson, any bleeding in the lungs is
considered to be diffuse alveolar hemorrhage,” Dr. Couriel said.
“Total body irradiation and infection (both fungal and viral)
probably account for most cases.”


Graft Failure

Graft failure, of course, is often a devastating complication.
“We usually think about graft failure when the neutrophil count
has not gone beyond 500 in a consistent way after day 25 or day
30,” Dr. Couriel said. “It is most often immune
mediated—graft ‘rejection’—but we rarely find the
exact etiology.”

Some of the factors that can lead to graft rejection are persistence
of host T cells (not as common with today’s preparatory
regimens) and, in heavily transfused patients, post-transfusion
alloim-munization (host lymphocytotoxic antibodies). Immune-mediated
problems are more common when the transplant involves greater HLA
disparity or HLA class I disparity, especially HLA-C.

Non-immune-mediated causes of graft failure include stem cell damage,
viral infections, and drug toxicity. “There’s a long list
of drugs that can lead to graft failure,” Dr. Couriel said.
“One of the most common is ganciclovir [Cytovene], which we use
for cytomegalovirus prophylaxis.”

He noted that graft failure has a very high mortality—over 90%.
“You can try growth factors. If there’s no response, you
have to reinfuse—but to reinfuse, you have to immunosuppress.
It’s a very bad situation,” he said.


Infection a Long-Term Concern

Infection is a significant, long-term concern among transplant
recipients, Dr. Couriel said. Supportive care includes prophylaxis
for bacteria, fungi, Pneumocystis carinii pneumonia (PCP), and
viruses.

Penicillin or norfloxacin (Noroxin) typically is given to prevent
bacterial infections until engraftment occurs, he said.

Prophylaxis for fungal infections—with fluconazole (Diflucan) or
itra-conazole (Sporanox), or liposomal amphotericin B (Abelcet)—
is started 5 days before transplantation and continues to day 100.

To prevent PCP, trimethoprim/sulfamethoxazole (Bactrim and others) is
started 8 days before infusion, then stopped 2 days before transplant
(because of concerns about myelosup-pression in the postconditioning,
post-infusion period). It is then started again after engraftment.
Bactrim prophylaxis continues for 6 months to 1 year.

Cytomegalovirus (CMV) prophylaxis consists of using only seronegative
blood products or leukocyte filters in seronegative patients.
Seropositive recipients can receive “primary prophylaxis”
with ganciclovir at the time of engraftment—a controversial
practice—or the more accepted “preemptive treatment”
with ganciclovir when the virus reactivates.

At M.D. Anderson, ganciclovir is started when a viral protein
associated with reactivation is detected in the blood—a practice
that has significantly reduced CMV mortality, Dr. Couriel said.


Acute GVHD

GVHD is a major complication in allogeneic stem cell transplants.
Predisposing factors include HLA disparity, advancing age, gender
mismatch (female-to-male transplants, in part because the graft
recognizes the Y chromosome as foreign), donor parity, CMV infection,
type of graft (umbilical cord, peripheral blood stem cell, or T
cell-depleted graft), and, for chronic GVHD, a history of acute GVHD.

The risk of developing acute GVHD after an allogeneic stem cell
transplant ranges from 10% to 100%, depending on the conditioning
regimen, predisposing factors, and the degree of graft manipulation.
“We tell our patients that with an unmanipulated HLA-matched
graft, the risk of any degree of GVHD is 30% to 40%,” Dr.
Couriel said.

The severity of acute GVHD is based on the extent and degree of
target organ involvement—skin, gut, and liver. Standard
prophylaxis has been cyclosporine (Neoral, Sandimmune) or tacrolimus
(Prograf) plus methotrexate. Four or five years ago, cyclosporine
plus prednisone was used, Dr. Couriel noted, but M.D. Anderson
prefers to use tacrolimus plus prednisone.

Established acute GVHD is treated with methylprednisolone (while
continuing cyclosporine or tacrolimus). Steroid-refractory patients,
who have a mortality of more than 50%, are given antithy-mocyte
globulin (Atgam) or experimental immunomodulating agents.


Chronic GVHD

Chronic GVHD is defined as GVHD that persists after day 100—a
demarcation that is “really arbitrary,” he said.

“Classically, every organ site is involved,” Dr. Couriel
said. “And chronic GVHD appears to be a different disease from
acute GVHD. It is more the result of persistent autoimmune attack,
and, in a way, it mimics autoimmune diseases like systemic lupus
erythematosus and scleroderma.”

The clinical manifestations of chronic GVHD, he said, can include
lichenoid and sclerodermal skin rashes; oral lichenoid changes, dry
mouth, and altered taste; dry eyes and corneal erosions; anorexia,
nausea, and chronic diarrhea; liver dysfunction; musculoskeletal
con-tractures and arthritis; and repeated infections.

Treatment is immunosuppression, primarily with methylprednisolone and
tacrolimus or, for localized skin or mouth involvement, topical
steroids.

The specific treatment approach depends on the nature of the
disease—de novo (no history of acute GVHD), progressive, or
relapsing; clinical vs subclinical; extensive vs limited; high-risk
(platelets less than 100,000) vs low-risk; and early vs late
complications.

Resource Topics rightRail

  • Resource Topics
  • Partner Content
Breast Cancer
Lung Cancer
Prostate Cancer
Colorectal Cancer
Melanoma
Cutaneous T-Cell Lymphomas: Mycosis Fungoides and Sézary Syndrome
3 Keys to Success in the Oncology Care Model

Current Issue

Oncology Vol 32 No 4
Apr 15, 2018 Vol 32 No 4
Digital Edition
Subscribe
Connect with Us
  • Twitter
  • Facebook
  • LinkedIn
  • RSS
Modern Medicine Network
  • Home
  • About Us
  • Advertise
  • Advertiser Terms
  • Privacy statement
  • Terms & Conditions
  • Editorial & Advertising Policy
  • Editorial Board
  • Contact Us
Modern Medicine Network
© UBM 2018, All rights reserved.
Reproduction in whole or in part is prohibited.